|
14:35–15:00
|
Developing an mRNA Vaccine against SARS-CoV2 in Lightspeed
Özlem Türeci (Mainz/DE) Talk time: 20 + 5 min |
|
||
|
15:00–15:25
|
PT 6 |
Rapid response to SARS-CoV-2 enabled by mRNA technology
Darin Edwards (Cambridge, MA/US) Talk time: 20 + 5 min |
|
|
|
15:25–15:50
|
PT 7 |
Development of ChAdOx1 nCoV-19
Sarah Gilbert (Oxford/GB) Talk time: 20 + 5 min |
|
|
|
15:50–16:15
|
Janssen’s efforts in the development of a
COVID-19 Vaccine
Roland Zahn (Leiden/NL) Talk time: 20 + 5 min |
|
||
|
16:15–16:40
|
PT 9 |
The DZIF COVID-19 candidate vaccine MVA-SARS-2-S
Gerd Sutter (München/DE) Talk time: 20 + 5 min |
|
|
|
16:40–17:05
|
PT 10 |
Antibody-mediated SARS-CoV-2 Neutralization
Florian Klein (Köln/DE) Talk time: 20 + 5 min |
|
|